17th Sep 2007 09:00
Physiomics PLC17 September 2007 Collaboration with Eli Lilly Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, ispleased to announce that it has signed an agreement with Eli Lilly and Company('Lilly') (NYSE: LLY), the global pharmaceutical company, to provide in silicosimulations of cancer cellular processes in support of Lilly's cancer drugdiscovery research. Physiomics will deploy its modelling expertise in biological systems, in closecollaboration with Lilly's global PK/PD/TS (pharmacokinetics, pharmacodynamicsand trial simulation) department and oncology discovery group. The researchprogramme will initially be focused on drugs targeting the cell cycle (thenatural process of controlling cell proliferation) - a process that isfrequently disrupted in cancers. Dr Christophe Chassagnole, COO of Physiomics, said: 'We are delighted that Lilly has chosen Physiomics as a partner in the systemsbiology field applied to our special focus area of oncology. This is a verypositive step forward for Physiomics as a further major pharma company joins ourgrowing list of partners at a time when interest in application of systemsbiology to pharma R&D is increasing very rapidly.' Contact Details: Physiomics plc: Dr Christophe Chassagnole, phone +44 (0)1865 784982E-mail: [email protected] Grant Thornton Corporate Finance: Philip Secrett and Colin Aaronson, phone +44 (0) 20 7383 5100 Information on Physiomics plcPhysiomics plc (AIM:PYC) is a computational systems biology services companyapplying simulations of cell behaviour to drug development to reduce the highattrition rates of clinical trials. As 80-90 per cent of all clinical drugcandidates fail to reach the market, estimates1 show that an overall ten percent improvement in success rates could reduce the cost of one drug'sdevelopment by as much as $242 million, from the current estimate of around $800million. Physiomics develops computational systems biology models to predict andunderstand cancer drug efficacy from pre-clinical research to clinicaldevelopment. Physiomics has created detailed mathematical models incorporatingmost important molecular events taking place during the human cell cycle andapoptosis processes. Physiomics developed SystemCell(R) technology, a multi-cellular environment software, which enables the simulation of population of"virtual cells". Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIMin 2004. For further information, please visit www.physiomics-plc.com SystemCell(R) is a registered trademark of Physiomics plc 1 Tufts Center Impact Report 2002 END This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Physiomics